805TiPRANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303).
نویسندگان
چکیده
S. Williams1, I.D. Davis2, C. Sweeney3, M.R. Stockler4, A. Martin4, A.P. Long4, S. Yip4, X. Coskinas4, P. Nguyen5 Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, AUSTRALIA Eastern Health Clinical School, Monash University, Melbourne, VIC, AUSTRALIA Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, AUSTRALIA Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA
منابع مشابه
Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer
Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...
متن کاملPost hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
BACKGROUND Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR], 0.19; P < .0001) and reduced the risk of death by 29% (HR, 0.71; P < .0001) compared with placeb...
متن کاملHormone Therapy for Prostate Cancer: Exploring Current Controversies
65.[13] Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): an open randomised phase III trial. Lancet 2009;373: 301–8.[14] D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–95.<...
متن کاملLocalised prostate cancer - current treatment options.
BACKGROUND A number of options are available to treat localised prostate cancer, with different side effect profiles, effect on quality of life and social costs. OBJECTIVE This article outlines the grading and staging of localised prostate cancer and explores the role of each of the treatment options currently available. DISCUSSION Treatment selection in localised prostate cancer depends on...
متن کاملThe role of surgery in high-risk localised prostate cancer.
• The optimal management of high-risk localised prostate cancer is a major challenge for urologists and oncologists. It is clear that multimodal therapy including radical local treatment is needed in these men to achieve the best outcomes. • External beam radiotherapy (EBRT) is an essential component of therapy either as a primary or adjuvant treatment. However, the role of radical prostatectom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014